Testosterone does not make breasts bigger in females. It does the opposite. Testosterone actively inhibits breast tissue growth and, over time, causes the glandular tissue in the breast to shrink. Whether testosterone is produced naturally in excess or taken externally, the consistent effect on female breast tissue is reduction, not enlargement.
How Testosterone Affects Breast Tissue
Breast development in females is driven primarily by estrogen, which stimulates the milk-producing glands and ductal system to grow. Testosterone works directly against this process. The balance between these two hormones is what determines how much breast tissue develops and how much is maintained over time. Estrogen stimulates, while testosterone inhibits, and this holds true regardless of genetic sex.
Testosterone slows breast cell growth through at least two mechanisms. It acts directly on androgen receptors in breast tissue to suppress proliferation. It also reduces the number of estrogen receptors on breast cells, making them less responsive to estrogen’s growth signals. In primate studies, even low doses of testosterone in the normal female range significantly inhibited estrogen-driven breast cell proliferation. When researchers blocked the body’s natural androgen receptors in cycling monkeys, breast cell proliferation increased, confirming that even the small amount of testosterone females normally produce plays a role in keeping breast growth in check.
What Happens With Prolonged Exposure
The longer breast tissue is exposed to elevated testosterone, the more it changes. Research on trans masculine individuals taking testosterone therapy provides the clearest picture of this timeline. After 12 or more months of use, 58.3% of breast tissue samples showed moderate to marked lobular atrophy, compared to 32.9% in those not using testosterone. For every six months of testosterone use, the amount of breast epithelium (the functional glandular tissue) decreased by about 3%, and the surrounding supportive tissue decreased by about 1%.
These changes are cumulative. The degree of lobular atrophy correlated directly with how long someone had been taking testosterone. This means breast tissue doesn’t simply stop growing; it actively breaks down and thins out the longer testosterone levels stay elevated.
Fat Redistribution Plays a Role Too
Breasts aren’t only glandular tissue. A significant portion of breast volume comes from fat. Testosterone shifts where the body stores fat, pulling it away from the hips, thighs, and chest and depositing more around the abdomen. This “android” fat pattern is typical in males and in females with elevated testosterone. So even beyond its direct effects on glandular tissue, testosterone can reduce breast size by redistributing the fat that gives breasts much of their volume.
Research on transgender women (who suppress testosterone and take estrogen) found that differences in breast development between individuals were largely explained by differences in body fat percentage rather than prior testosterone exposure. Once fat percentage was accounted for, the gap in breast volume nearly disappeared. This underscores how much of breast size is tied to fat, and how testosterone’s effect on fat storage matters for visible breast size.
PCOS: A Complicating Factor
Polycystic ovary syndrome is the most common cause of elevated testosterone in women of reproductive age. You might expect PCOS to shrink breasts, and in some cases it does contribute to underdevelopment. But the hormonal picture in PCOS is more complicated than simply “high testosterone.”
Women with PCOS are about 2.5 times more likely to develop fibrocystic breast changes, which involve lumpy, sometimes painful areas of thickened tissue and fluid-filled cysts. This happens through a couple of pathways. The excess androgens can suppress progesterone, which paradoxically allows certain types of breast cell proliferation to continue unchecked. Androgens can also be converted into estrogen by an enzyme in fat tissue, and since many women with PCOS carry extra weight, this conversion can be significant.
In one study, nearly 40% of women with PCOS had fibrocystic breast changes compared to 12.5% of women without the condition. Another study found the difference even more dramatic: 92% versus 7%. These changes can make breasts feel fuller, denser, or lumpier, but this isn’t the same as healthy breast growth. It’s a pathological change driven by hormonal imbalance, not a cosmetic increase in breast size from testosterone itself.
Anabolic Steroids and Breast Shrinkage
The NHS lists decreased breast size as a known effect of anabolic steroid use in women. Anabolic steroids are synthetic versions of testosterone, and they produce the same anti-proliferative effects on breast tissue as the natural hormone, often more aggressively because the doses involved tend to be much higher than what the body produces on its own.
Women who use anabolic steroids commonly report breast shrinkage alongside other virilizing effects like increased body hair, deepening voice, and clitoral enlargement. Breast atrophy (mammary atrophy) is in fact listed as a standard clinical sign of hyperandrogenism and virilization in medical literature, right alongside acne, hair loss on the scalp, and increased muscle mass.
Is the Shrinkage Reversible?
This is where the evidence gets less reassuring. The glandular atrophy caused by testosterone is progressive and cumulative. The research shows a clear dose-duration relationship: more time on testosterone means more tissue breakdown. What remains unclear is how much of this reverses if testosterone levels return to normal.
Fat redistribution is generally reversible. If testosterone levels drop and estrogen becomes dominant again, the body tends to shift fat back toward a typical female pattern over months to years, which can restore some breast volume. But the glandular tissue is a different story. Lobular atrophy that has progressed to moderate or marked levels may not fully recover, particularly after years of elevated testosterone. Being overweight or obese does appear to offer some protection, as the effect of testosterone on breast epithelium is attenuated in people with higher body fat, likely because fat tissue continues producing estrogen locally.
For women whose testosterone is elevated due to a treatable condition like a hormone-producing ovarian tumor, correcting the underlying cause allows estrogen to regain dominance and may permit partial recovery of breast tissue. How complete that recovery is depends on how long testosterone was elevated and how high levels were.